Finally, the approval of the monoclonal HER2-targeted antibody trastuzumab for the treatment of advanced or metastatic gastric cancer showed the potential of targeted therapies in this illness (Bang et al. 2010). The gene discussed is ERBB2; the disease is gastric cancer.